证券代码：002584 证券简称：西陇科学 公告编号：2025-050 西陇科学股份有限公司 关于母公司为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 本次担保额度有效期自公司 2024 年度股东大会批准之日起至 2025 年度股东 大会召开之日止，有效期内担保额度可循环使用。 公告内容详见公司 2025 年 4 月 26 日于指定信息披露媒体披露的《西陇科学： 关于公司及子公司对 2025 年度融资授信提供担保的公告》（公告编号：2025-016）， 本议案已经由公司 2024 年度股东大会审议通过。 二、 担保进展情况 公司与九江银行股份有限公司广州分行签订《最高额保证合同》，为子公司 佛山西陇化工有限公司在九江银行股份有限公司广州分行办理的《流动资金借款 1 一、 担保情况概述 西陇科学股份有限公司（以下简称"西陇科学"或"公司"）第六届董事会第八 次会议审议通过了《关于公司及子公司对 2025 年度融资授信提供担保的议案》。 2025 年度，根据公司及子（孙）公司的生产经营和资金需求情况，公司及子（孙） 公司为合并报表范围内 ...

Company Overview - Xilong Scientific Co., Ltd. is located in Huangpu District, Guangzhou, Guangdong Province, and was established on July 19, 1994. The company was listed on June 2, 2011. Its main business involves the research, production, and sales of chemical reagents, as well as some chemical raw materials, active pharmaceutical ingredients, and food additives [2] - The revenue composition of Xilong Scientific includes: specialized chemicals 62.60%, chemical raw materials 15.12%, electronic chemicals 9.66%, general reagents 7.71%, lithium battery cathode materials 4.00%, active pharmaceutical ingredients and food additives 0.86%, and others 0.04% [2] - As of June 30, the number of shareholders of Xilong Scientific was 87,100, an increase of 8.25% from the previous period, with an average of 5,375 circulating shares per person, an increase of 0.06% [2] Financial Performance - For the first half of 2025, Xilong Scientific achieved operating revenue of 3.368 billion yuan, a year-on-year decrease of 14.78%. The net profit attributable to the parent company was -75.3173 million yuan, a year-on-year decrease of 276.35% [2] - Since its A-share listing, Xilong Scientific has cumulatively distributed cash dividends of 217 million yuan, with a total of 31.0165 million yuan distributed in the past three years [3] Stock Performance - On September 29, Xilong Scientific's stock price fell by 2.04%, closing at 9.12 yuan per share, with a trading volume of 274 million yuan and a turnover rate of 6.33%. The total market capitalization was 5.337 billion yuan [1] - Year-to-date, Xilong Scientific's stock price has increased by 26.84%, with a decline of 3.49% over the last five trading days, a rise of 4.23% over the last 20 days, and a decline of 4.40% over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" five times this year, with the most recent appearance on September 24, where the net buying on that day was 3.6192 million yuan, accounting for 9.07% of the total trading volume [1]

Core Viewpoint - The actual controllers of Xilong Science plan to reduce their holdings by a total of 17.56 million shares, accounting for 3% of the total share capital, to meet personal financial needs and repay pledged financing [2][3][5] Shareholder Reduction Plan - Huang Weibao plans to reduce 9,456,400 shares, representing 1.62% of the total shares - Huang Weipeng plans to reduce 4,000,000 shares, representing 0.68% of the total shares - Huang Zhenkai plans to reduce 1,200,000 shares, representing 0.21% of the total shares - Huang Zhenjie plans to reduce 2,900,000 shares, representing 0.50% of the total shares - The total reduction amounts to 17,556,400 shares, or 3.00% of the total shares [3] Financial Performance - In the first half of 2025, Xilong Science achieved revenue of 3.368 billion yuan, a year-on-year decrease of 14.78% - The company reported a net loss of 75.32 million yuan, a shift from profit to loss compared to the previous year - The net profit excluding non-recurring items was 39.58 million yuan, a year-on-year decrease of 3.90% - The revenue decline was primarily due to reduced income from chemical raw material trading and specialized chemical products [4] Control and Governance - If the planned share reduction is fully executed, the actual controllers and their concerted actors will still hold 22.61% of Xilong Science's shares - This reduction will not lead to a change in control and will not adversely affect the governance structure or ongoing operations of the company [5]

Core Viewpoint - The stock of Xilong Science increased by 2.45% today, with a turnover rate of 28.84% and a trading volume of 1.319 billion yuan, indicating significant trading activity and interest in the stock [2]. Trading Activity - The stock was listed on the Dragon and Tiger list due to its turnover rate reaching 28.84%, with institutional investors net selling 17.9684 million yuan [2]. - The top five trading departments accounted for a total transaction volume of 236 million yuan, with a net buying amount of 3.6192 million yuan [2]. - Among the trading departments, two institutional special seats were involved, with total buying amounting to 21.724 million yuan and selling amounting to 39.6924 million yuan, resulting in a net sell of 17.9684 million yuan [2]. Fund Flow - The stock experienced a net inflow of 479,700 yuan from major funds today, with a significant inflow of 32.7653 million yuan from large orders, while large orders saw a net outflow of 32.2856 million yuan [3]. - Over the past five days, the stock has seen a net inflow of 224 million yuan from major funds [3]. Historical Performance - In the past six months, the stock has appeared on the Dragon and Tiger list five times, with an average price drop of 0.38% the day after being listed and an average increase of 1.70% over the following five days [3].

Core Viewpoint - Xilong Science has shown a significant stock price increase this year, with a notable rise in trading activity and fluctuations in net inflow and outflow of funds [1][2]. Group 1: Stock Performance - As of September 24, Xilong Science's stock price increased by 2.03%, reaching 9.56 CNY per share, with a total market capitalization of 5.595 billion CNY [1]. - The stock has risen 32.96% year-to-date, with a 11.68% increase over the last five trading days and a 7.66% increase over the last twenty days, while it has decreased by 3.43% over the last sixty days [1]. - The company has appeared on the trading leaderboard four times this year, with the most recent instance on May 23, where it recorded a net buy of -89.7156 million CNY [1]. Group 2: Financial Performance - For the first half of 2025, Xilong Science reported a revenue of 3.368 billion CNY, representing a year-on-year decrease of 14.78%, and a net profit attributable to shareholders of -75.3173 million CNY, a decline of 276.35% [2]. - The company has distributed a total of 2.17 billion CNY in dividends since its A-share listing, with 31.0165 million CNY distributed over the past three years [3]. Group 3: Business Overview - Xilong Science, established on July 19, 1994, and listed on June 2, 2011, is primarily engaged in the research, production, and sales of chemical reagents, with a revenue composition of 62.60% from specialized chemicals, 15.12% from chemical raw materials, and 9.66% from electronic chemicals [2]. - The company operates within the electronic chemical industry and is involved in various sectors, including gene sequencing, nuclear pollution prevention, photolithography, food safety, and assisted reproduction [2].

Summary of Key Points Core Viewpoint - The company, Xilong Science Co., Ltd., has announced the progress of providing guarantees within the scope of consolidated financial statements for financing credit applications in 2025, with a total guarantee amount not exceeding RMB 3.75 billion. Group 1: Guarantee Overview - The company and its subsidiaries will provide guarantees for financing credit applications to financial institutions, with a total guarantee amount not exceeding RMB 3.75 billion for 2025 [2]. - The company will guarantee up to RMB 2.085 billion for its subsidiaries, with specific limits based on their asset-liability ratios: RMB 1.635 billion for subsidiaries with an asset-liability ratio of 70% or less, and RMB 450 million for those exceeding 70% [2]. - Subsidiaries will also provide guarantees for each other, totaling up to RMB 55 million, with similar asset-liability ratio conditions [2]. Group 2: Guarantee Progress - The company has signed a maximum guarantee contract with Huishang Bank Shenzhen Branch, providing a joint liability guarantee of up to RMB 13 million for Guangzhou Xilong Fine Chemical Technology Co., Ltd. [4]. - Another contract was signed with Huishang Bank Shenzhen Branch for Foshan Xilong Chemical Co., Ltd., also providing a joint liability guarantee of up to RMB 13 million [4]. - Guangzhou Xilong Innovation Park Management Co., Ltd. has signed a maximum guarantee contract with Guangzhou Huangpu Ronghe Village Bank, providing a joint liability guarantee of up to RMB 16 million for Guangzhou Xilong Fine Chemical Technology Co., Ltd. [4]. Group 3: Guarantee Agreement Details - The guarantees cover principal debts, interest, penalties, and other related costs, with a guarantee period of three years from the debt fulfillment date [6][7]. - The maximum guarantee amounts for the contracts with Huishang Bank are RMB 13 million each, while the contract with Guangzhou Huangpu Ronghe Village Bank has a maximum guarantee of RMB 16 million [6][8]. - As of the announcement date, the company and its subsidiaries have a total external guarantee amount of zero, with specific internal guarantees totaling RMB 870.16 million, RMB 757.77 million, and RMB 16 million for various subsidiaries [8].

（文章来源：证券日报） 证券日报网讯 9月23日晚间，西陇科学发布公告称，公司及控股子公司均不存在逾期担保情况。 ...

Group 1 - Qianyu Medical's shareholder QM5 LIMITED plans to transfer approximately 6.6693 million shares, accounting for 2% of the company's total share capital [1] - Guizhou Platinum Industry intends to raise no more than 1.291 billion yuan for technological innovation platform construction, industrial transformation, and working capital [1] - Guangdong Construction has won a bid for the Guangzhou Financial City East District project with a contract value of 1.924 billion yuan [1] Group 2 - Sanfu New Science plans to repurchase shares with a total amount not less than 10 million yuan and not exceeding 15 million yuan [3] - Baiyun Mountain's subsidiary has entered the II phase of clinical trials for children's Xiao Chai Hu granules, aimed at treating pediatric gastrointestinal colds [4] - Lepu Medical has signed a strategic cooperation agreement with Hanhai Information for market promotion and operation rights in mainland China [5] Group 3 - Daotong Technology plans to transfer 46% of its stake in Saifang Technology for a total consideration of 109 million yuan [7] - Rizhao Port's shareholder Shandong Energy Group intends to reduce its stake by up to 3% [8] - Saiwei Electronics reports that the National Integrated Circuit Fund has reduced its stake by 6.3481 million shares, representing 0.87% of the total share capital [10] Group 4 - Changji Logistics proposes a cash dividend of 0.31 yuan per share for the 2025 interim period [11] - Xuelong Group's shareholder plans to reduce its stake by up to 1.95% [13] - Lianxiang Co. plans to reduce its stake by a total of 3.74% [15] Group 5 - Yingfeite's actual controller plans to reduce its stake by up to 2.82% [16] - Baolong Technology's director plans to reduce his stake by up to 0.11% [17] - China Electric Research's shareholder plans to transfer 2% of the company's shares through an inquiry transfer [18] Group 6 - Oriental Pearl plans to participate in establishing an investment fund with a total fundraising scale of 714 million yuan [19] - Tianqin Equipment's shareholder plans to reduce its stake by up to 1% [21] - Crystal Optoelectronics' shareholder plans to reduce its stake by up to 0.99% [22] Group 7 - Changchun Technology expects a net profit increase of 131.39% to 145.38% for the first three quarters of 2025 [22] - Jinhai Tong's shareholder plans to reduce its stake by up to 1% [24] - Zhongdian Electric's shareholder plans to reduce its stake by up to 3% [26] Group 8 - Zhixiang Jintai has signed exclusive cooperation agreements for two monoclonal antibody injections [27] - Chuangli Group's director plans to reduce his stake by up to 0.7% [28] - Henghui Security's shareholders plan to reduce their stake by a total of 2.34% [29] Group 9 - Tianci Materials' subsidiary has signed a supply cooperation agreement for no less than 800,000 tons of electrolyte products [29] - Tianci Materials has submitted an application for H-share listing on the Hong Kong Stock Exchange [30] - Zhongke Haixun has signed a strategic cooperation agreement with Beibu Gulf Port Group [30] Group 10 - China CNR has elected Sun Yongcai as the chairman of the board [31] - Baiwei Storage plans to issue H-shares and list on the Hong Kong Stock Exchange [32] - Shengxin Lithium Energy plans to acquire a 21% stake in Qicheng Mining for 1.456 billion yuan [33] Group 11 - Zhongjing Electronics plans to raise no more than 700 million yuan for various projects [35] - Dingxin Communications clarifies that its technology authorization from Pingtouge is unrelated to AI intelligent reasoning chips [37] - Rihai Intelligent's major shareholder plans to reduce its stake by up to 2.77% [38] Group 12 - Rihai Optical's actual controller plans to reduce his stake by up to 3% [39] - Xilong Science's actual controllers plan to reduce their stake by a total of 3% [40] - Honggong Technology plans to sign a project contract with a maximum investment of 450 million yuan [41] Group 13 - Mankang Pharmaceutical has signed a strategic cooperation agreement with Nanjing Haijing Pharmaceutical [42] - Mankang Pharmaceutical plans to raise no more than 1.033 billion yuan through a private placement [42] - Kaidi Co.'s shareholder plans to reduce its stake by up to 38,030 shares [43] Group 14 - Hesheng Co. has launched a stock option and restricted stock incentive plan totaling 3.6 million shares [44] - ST Yigou's shareholder plans to reduce its stake by up to 2.85% [46] - Jinziham's subsidiary plans to invest up to 300 million yuan in Zhongzheng Microelectronics [49]

证券代码：002584 证券简称：西陇科学 公告编号：2025-048 西陇科学股份有限公司 关于合并报表范围内提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、 担保情况概述 西陇科学股份有限公司（以下简称"西陇科学"或"公司"）第六届董事会第八 次会议审议通过了《关于公司及子公司对 2025 年度融资授信提供担保的议案》。 2025 年度，根据公司及子（孙）公司的生产经营和资金需求情况，公司及子（孙） 公司为合并报表范围内公司向金融机构申请融资授信提供担保，担保额度总计不 超过人民币 37.5 亿元。具体如下： 公司为纳入合并报表范围的子（孙）公司向金融机构申请融资授信提供担保， 总额不超过人民币20.85亿元，其中对最近一期资产负债率小于等于70%的子（孙） 公司担保额度不超过人民币 16.35 亿元，对最近一期资产负债率超 70%的子（孙） 公司担保额度不超过人民币 4.5 亿元；子（孙）公司为合并范围内其他子（孙） 公司向金融机构申请融资授信提供担保，总额不超过人民币 0.55 亿元，其中对最 近一期资产负债率小于等于 70%的 ...

中国经济网北京9月23日讯 西陇科学（002584.SZ）昨日晚间披露《关于部分实际控制人减持股份 的预披露公告》。 根据公告，部分实际控制人黄伟波、黄伟鹏、黄侦凯、黄侦杰计划通过集中竞价交易方式和大宗交 易方式减持其持有的公司股份合计不超过17,556,400股，即不超过公司总股本的3.00%。 其中以集中竞价交易拟减持所持股份合计不超过5,852,100股（占公司总股本的1.00%），以大宗交 易拟减持所持股份合计不超过11,704,300股（占公司总股本的2.00%）。 按上一交易日公司收盘价9.45元计算，黄伟波、黄伟鹏、黄侦凯、黄侦杰拟减持套现合计约 165,907,980元。 截至公告披露日，黄伟波持有西陇科学37,934,656股，占公司总股本比例6.48%；黄伟鹏持有 38,729,941股，占公司总股本比例6.62%；黄侦凯持有4,932,625股，占公司总股本比例0.84%；黄侦杰持 有11,747,500股，占公司总股本比例2.01%。 据新浪财经信息，黄伟波最初持股3660万股，占总股本的18.30%。黄伟波从2016年6月17日起，第 一次减持西陇科学股份，迄今为止，累计减持公司股票 ...